Orchid Cellmark

Orchid has acquired the paternity and immigration DNA testing business unit from Strand Analytical Laboratories.

A life sciences fund run by Accipiter Capital Management has nominated three new members to be Class I directors on Orchid Cellmark's board.

Orchid also turned a profit for the quarter, as it recognized license fees from a deal with Illumina.

The company will provide DNA testing for five years under a $5.2 million contract.

The Australian firm has taken aim at several firms in the research, molecular diagnostics, and agricultural genomics fields for allegedly infringing its patent covering methods of analyzing non-coding DNA sequences.

The company expects the move to result in $1.4 million in annual cost savings.

CEO Kevin McElfresh said Casework hopes to commercialize the technique, which uses the Illumina HumanOmni1-Quad BeadChip, by year end in order to upgrade its own offering and gain an advantage over rivals that use older technology.

The DNA testing firm sees the closure of a facility in Michigan saving it around $1 million per year.

The license gives Orchid up to $1 million in fees, as well as royalties and preferred customer status.

Excluding the impact of currency, Orchid Cellmark's revenues were up 9 percent for the quarter.


An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.